Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

international flavors & fragrances inc. - IFF

IFF

Close Chg Chg %
66.49 0.67 1.01%

Closed Market

67.16

+0.67 (1.01%)

Volume: 2.05M

Last Updated:

Dec 5, 2025, 3:59 PM EDT

Trade Now

Company Overview: international flavors & fragrances inc. - IFF

IFF Key Data

Open

$66.30

 Day Range

66.30 - 67.95

52 Week Range

59.14 - 90.63

 Market Cap

$17.03B

Shares Outstanding

256.10M

 Public Float

250.99M

Beta

1.04

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.61

Yield

238.38%

 Dividend

$0.40

EX-DIVIDEND DATE

Dec 19, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.27M

  

IFF Performance

1 Week
 
 -4.30%
 
1 Month
 
 7.24%
 
3 Months
 
 0.70%
 
1 Year
 
 -25.22%
 
5 Years
 
 -42.68%
 

IFF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About international flavors & fragrances inc. - IFF

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.

IFF At a Glance

International Flavors & Fragrances, Inc.
521 West 57th Street
New York, New York 10019-2960
Phone 1-212-765-5500 Revenue 11.48B
Industry Food: Specialty/Candy Net Income 243.00M
Sector Consumer Non-Durables 2024 Sales Growth 0.044%
Fiscal Year-end 12 / 2025 Employees 22,400
View SEC Filings

IFF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 89.075
Price to Sales Ratio 1.885
Price to Book Ratio 1.558
Price to Cash Flow Ratio 20.23
Enterprise Value to EBITDA 14.046
Enterprise Value to Sales 2.685
Total Debt to Enterprise Value 0.312

IFF Efficiency

Revenue/Employee 512,678.571
Income Per Employee 10,848.214
Receivables Turnover 6.466
Total Asset Turnover 0.385

IFF Liquidity

Current Ratio 1.845
Quick Ratio 1.352
Cash Ratio 0.108

IFF Profitability

Gross Margin 30.582
Operating Margin 10.275
Pretax Margin 2.421
Net Margin 2.116
Return on Assets 0.815
Return on Equity 1.706
Return on Total Capital 1.034
Return on Invested Capital 1.046

IFF Capital Structure

Total Debt to Total Equity 69.336
Total Debt to Total Capital 40.946
Total Debt to Total Assets 33.561
Long-Term Debt to Equity 58.489
Long-Term Debt to Total Capital 34.541
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for International Flavors & Fragrances Inc. - IFF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
11.66B 12.44B 11.48B 11.48B
Sales Growth
+129.26% +6.73% -7.73% +0.04%
Cost of Goods Sold (COGS) incl D&A
8.65B 9.02B 8.48B 7.97B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.16B 1.18B 1.14B 1.01B
Depreciation
424.00M 452.00M 462.00M 405.00M
Amortization of Intangibles
732.00M 727.00M 680.00M 610.00M
COGS Growth
+170.88% +4.17% -5.94% -5.99%
Gross Income
3.00B 3.42B 3.00B 3.51B
Gross Income Growth
+58.86% +14.10% -12.41% +17.11%
Gross Profit Margin
+25.75% +27.52% +26.13% +30.58%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.11B 2.28B 2.17B 2.33B
Research & Development
629.00M 603.00M 636.00M 671.00M
Other SG&A
1.48B 1.67B 1.53B 1.66B
SGA Growth
+80.95% +7.97% -4.79% +7.56%
Other Operating Expense
- - - -
-
Unusual Expense
309.00M 2.47B 2.96B 595.00M
EBIT after Unusual Expense
583.00M (1.32B) (2.12B) 585.00M
Non Operating Income/Expense
59.00M 33.00M (14.00M) (2.00M)
Non-Operating Interest Income
- - - 15.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
288.00M 336.00M 380.00M 305.00M
Interest Expense Growth
+119.94% +16.67% +13.10% -19.74%
Gross Interest Expense
288.00M 336.00M 380.00M 305.00M
Interest Capitalized
- - - -
-
Pretax Income
354.00M (1.63B) (2.52B) 278.00M
Pretax Income Growth
-19.80% -559.04% -54.95% +111.04%
Pretax Margin
+3.04% -13.06% -21.94% +2.42%
Income Tax
75.00M 239.00M 45.00M 31.00M
Income Tax - Current - Domestic
8.00M 151.00M 55.00M (49.00M)
Income Tax - Current - Foreign
303.00M 325.00M 359.00M 384.00M
Income Tax - Deferred - Domestic
(155.00M) (188.00M) (81.00M) (227.00M)
Income Tax - Deferred - Foreign
(81.00M) (49.00M) (288.00M) (77.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (2.00M) 3.00M 2.00M
Consolidated Net Income
277.00M (1.86B) (2.56B) 247.00M
Minority Interest Expense
9.00M 7.00M 4.00M 4.00M
Net Income
268.00M (1.87B) (2.56B) 243.00M
Net Income Growth
-26.38% -797.01% -37.31% +109.47%
Net Margin Growth
+2.30% -15.02% -22.35% +2.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
268.00M (1.87B) (2.56B) 243.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
268.00M (1.87B) (2.56B) 243.00M
EPS (Basic)
1.1029 -7.3255 -10.0588 0.9492
EPS (Basic) Growth
-66.02% -764.20% -37.31% +109.44%
Basic Shares Outstanding
243.00M 255.00M 255.00M 256.00M
EPS (Diluted)
1.1029 -7.3255 -10.0588 0.9492
EPS (Diluted) Growth
-65.57% -764.20% -37.31% +109.44%
Diluted Shares Outstanding
243.00M 255.00M 255.00M 256.00M
EBITDA
2.05B 2.33B 1.97B 2.19B
EBITDA Growth
+95.26% +13.57% -15.18% +11.25%
EBITDA Margin
+17.57% +18.70% +17.19% +19.11%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 81.269
Number of Ratings 22 Current Quarters Estimate 0.832
FY Report Date 12 / 2025 Current Year's Estimate 4.256
Last Quarter’s Earnings 1.05 Median PE on CY Estimate N/A
Year Ago Earnings 4.31 Next Fiscal Year Estimate 4.492
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 6 17 17
Mean Estimate 0.83 1.15 4.26 4.49
High Estimates 0.91 1.24 4.50 5.05
Low Estimate 0.66 1.10 4.05 4.25
Coefficient of Variance 8.17 4.62 2.40 4.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 12
OVERWEIGHT 5 6 5
HOLD 5 5 5
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for International Flavors & Fragrances Inc. - IFF

Date Name Shares Transaction Value
May 20, 2025 Stephen N. Landsman EVP, General Counsel 12,000 Open market or private purchase of non-derivative security Non-derivative transaction at $77.58 per share 930,960.00
May 20, 2025 Stephen N. Landsman EVP, General Counsel 10,000 Open market or private purchase of non-derivative security Non-derivative transaction at $77.22 per share 772,200.00
May 20, 2025 Beril Yildiz CAO, SVP & Controller 3,321 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $77.34 per share 256,846.14
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 6,206 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 9,553 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 698,515.36
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 10,132 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 740,851.84
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 10,362 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 9,859 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 32,883 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 25,436 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 1,859,880.32
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 27,981 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 12,213 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 13,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 9,485 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 693,543.20
Apr 8, 2025 Michael DeVeau CFO 9,947 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 727,324.64
Apr 8, 2025 Michael DeVeau CFO 10,204 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 9,492 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 7, 2025 Ana Paula Mendonça President, Scent 6,884 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 Ana Paula Mendonça President, Scent 452 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.64 per share 39,161.28

International Flavors & Fragrances Inc. in the News